<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390584</url>
  </required_header>
  <id_info>
    <org_study_id>E2410</org_study_id>
    <secondary_id>U01CA079778</secondary_id>
    <secondary_id>U01CA080098</secondary_id>
    <nct_id>NCT01390584</nct_id>
  </id_info>
  <brief_title>Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma</brief_title>
  <official_title>Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate,&#xD;
      vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride,&#xD;
      vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses&#xD;
      high-energy x rays to kill cancer cells. Giving combination chemotherapy together with&#xD;
      radiation therapy may kill more cancer cells. Comparing results of imaging procedures, such&#xD;
      as PET scans and CT scans, done before, during, and after chemotherapy may help doctors&#xD;
      predict a patient's response to treatment and help plan the best treatment.&#xD;
&#xD;
      PURPOSE: This phase II clinical trial studies how well chemotherapy based on PET/CT scan&#xD;
      works in treating patients with stage I or stage II Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the progression-free survival (PFS) at 36 months following registration for&#xD;
           patients who are positron emission tomography (PET) negative after 2 courses of ABVD,&#xD;
           and receive 4 additional courses of doxorubicin hydrochloride, bleomycin sulfate,&#xD;
           vinblastine, and dacarbazine (ABVD) followed by involved-nodal radiotherapy [INRT] of&#xD;
           30-30.6 Gy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the PET-negative rate after 2 courses of ABVD chemotherapy in patients with&#xD;
           stage I/II Hodgkin lymphoma with bulky mediastinal disease.&#xD;
&#xD;
        -  To evaluate the PFS at 36 months for patients who are PET positive after 2 courses of&#xD;
           chemotherapy and receive 4 courses of escalated bleomycin sulfate, etoposide,&#xD;
           doxorubicin hydrochloride, cyclophosphamide, vincristine sulfate, procarbazine&#xD;
           hydrochloride, and prednisone (BEACOPP) followed by INRT of 30-30.6 Gy.&#xD;
&#xD;
        -  To evaluate the complete response (CR) rate and overall survival (OS) for PET-positive&#xD;
           and PET-negative patients after 2 courses of ABVD.&#xD;
&#xD;
        -  To identify sites of relapse following combined-modality therapy (CMT) for patients with&#xD;
           large mediastinal adenopathy and correlate with RT fields.&#xD;
&#xD;
        -  To assess toxicity on both arms of study.&#xD;
&#xD;
        -  To assess reproductive function at baseline and at 3 years after ABVD or escalated&#xD;
           BEACOPP with specific serum markers.&#xD;
&#xD;
        -  To bank serum and plasma at baseline and selected time points to assess the prognostic&#xD;
           value of various markers such as, but not limited to, SCD30, IL10, CCL17, CCL22, and&#xD;
           MDC.&#xD;
&#xD;
        -  To create tissue microarrays (TMAs) from patient tumor blocks for future biomarker&#xD;
           assessment including, but not limited to, bcl-2, FOXP3, and macrophage content.&#xD;
&#xD;
        -  To measure serum TARC levels pre-treatment and post two courses of ABVD and correlate&#xD;
           with PET-CT findings (performed at same time points) and 3 year PFS.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  To assess the predictive value of fludeoxyglucose F 18 (18FDG) uptake, as measured by&#xD;
           semi-quantitative measurements including standard uptake variables (SUVs), with respect&#xD;
           to response at the end of chemotherapy and PFS.&#xD;
&#xD;
        -  To compare the predictive value for response and PFS of FDG uptake alone to that of FDG&#xD;
           uptake in combination with CT size change information.&#xD;
&#xD;
        -  To compare the predictive value for response and PFS of FDG uptake alone to that of FDG&#xD;
           uptake in combination with available serum and tissue molecular biomarkers.&#xD;
&#xD;
        -  To compare the results of the secondary imaging objectives with the corresponding CALGB&#xD;
           50801 results (contingent on reaching agreement with CALGB on the combined analysis of&#xD;
           the two studies).&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate&#xD;
      IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15.&#xD;
      Treatment repeats every 28 days for 2 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are then assigned to an intervention arm according to fludeoxyglucose F 18 (18 FDG)&#xD;
      positron emission tomography (PET)/computed tomography (CT) results (negative vs positive).&#xD;
&#xD;
        -  ABVD (18FDG-PET/CT negative): Patients receive doxorubicin hydrochloride, bleomycin&#xD;
           sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats&#xD;
           every 28 days for 4 courses in the absence of disease progression or unacceptable&#xD;
           toxicity. Within 3-6 weeks after completion of chemotherapy, patients undergo&#xD;
           involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.&#xD;
&#xD;
        -  Escalated or standard BEACOPP* (18FDG-PET/CT positive): Patients receive doxorubicin&#xD;
           hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60&#xD;
           minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO&#xD;
           on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment&#xD;
           repeats every 21 days for 4 courses in the absence of disease progression or&#xD;
           unacceptable toxicity. Within 3-6 weeks after completion of chemotherapy, patients who&#xD;
           achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week&#xD;
           for approximately 3½ weeks.&#xD;
&#xD;
      NOTE: *HIV-positive patients whose 18FDG-PET/CT scans are positive after two courses of&#xD;
      induction ABVD receive 4 courses of standard BEACOPP followed by INRT.&#xD;
&#xD;
      Patients undergo 18FDG-PET scans at baseline, and within 8-10 days after 2 courses of ABVD&#xD;
      induction chemotherapy. Patients also undergo 18FDG-PET/CT** scan within 3-8 weeks after&#xD;
      completion of 4 courses of BEACOPP and 6 courses of ABVD, and 3 months after completion of&#xD;
      INRT.&#xD;
&#xD;
      NOTE: **If PET/CT remains positive, then a biopsy may be performed if medically appropriate&#xD;
      or clinically feasible at the discretion of the treating physician. If biopsy is positive,&#xD;
      patients will be followed for survival and secondary malignancies or new primaries.&#xD;
&#xD;
      Patients may undergo blood sample collection for correlative studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3 months for 1 year, every&#xD;
      6 months for 2 years, and then annually for up to 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 2, 2012</start_date>
  <completion_date type="Actual">May 18, 2018</completion_date>
  <primary_completion_date type="Actual">April 9, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival Rate</measure>
    <time_frame>Assessed at 36 months</time_frame>
    <description>Progression-free survival is defined as the time from study entry to lymphoma progression or death from any cause. Proportion of patients who are progression-free and alive at 36 months will be reported. Progression is defined as appearance of any new lesions more than 1.5 cm in any axis, at least a 50% increase from nadir in sum of the product of the diameters (SPD) of any previously involved nodes or extranodal masses or the size of other lesions, or at least 50% increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in its short axis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Are PET Negative After Induction Treatment</measure>
    <time_frame>Assessed at end of Cycle 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival at 36 Months Among Patients Who Are PET Positive After Induction Treatment</measure>
    <time_frame>Assessed at 36 months</time_frame>
    <description>Progression-free survival is defined as the time from study entry to lymphoma progression or death from any cause. Proportion of patients who are progression-free and alive at 36 months will be reported. Progression is defined as appearance of any new lesions more than 1.5 cm in any axis, at least a 50% increase from nadir in sum of the product of the diameters (SPD) of any previously involved nodes or extranodal masses or the size of other lesions, or at least 50% increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in its short axis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate After Induction Treatment</measure>
    <time_frame>Assessed at end of Cycle 2</time_frame>
    <description>Complete response (CR) is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Assessed at 36 months</time_frame>
    <description>Overall survival is defined as the time from study entry to death or date last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sites of Relapse Following Combined Modality Treatment</measure>
    <time_frame>Assessed at 3, 12, 18, 24 and 36 months after INRT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Plasma Banking</measure>
    <time_frame>Baseline and post cycle 2</time_frame>
    <description>To bank serum and plasma at baseline and follow-up time point to assess the prognostic value of various markers, such as but not limited to, SCD30, IL10, CCL17, CCL22, and MDC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Assessment Using Tissue Microarrays (TMAs)</measure>
    <time_frame>Baseline and relapse/progression</time_frame>
    <description>To create TMAs from patient tumor blocks for future biomarker assessment including but not limited to bcl-2, FOXP3, and macrophage content.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Association Between Thymus and Activation-related Chemokine (TARC) Levels and PET-CT Findings as Well as 3-year PFS</measure>
    <time_frame>Baseline and cycle 2 for TARC assessments; 3 years for PFS</time_frame>
    <description>To measure serum TARC levels pre-treatment and after two cycles of ABVD and evaluate the associations between TARC levels and PET-CT findings as well as 3-year PFS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>ABVD + INRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.&#xD;
ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.&#xD;
BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>IV</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <arm_group_label>ABVD + INRT</arm_group_label>
    <other_name>Adriamycin R</other_name>
    <other_name>Rubex R</other_name>
    <other_name>Adriamycin RDF R</other_name>
    <other_name>Adriamycin PFS R</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>hydroxydaunomycin</other_name>
    <other_name>ADR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>IV</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <arm_group_label>ABVD + INRT</arm_group_label>
    <other_name>Blenoxane R</other_name>
    <other_name>BLM</other_name>
    <other_name>Bleo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>IV</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <arm_group_label>ABVD + INRT</arm_group_label>
    <other_name>Velban R</other_name>
    <other_name>vinblastine sulfate</other_name>
    <other_name>vincaleukoblastine</other_name>
    <other_name>VLB</other_name>
    <other_name>Velsar R</other_name>
    <other_name>Alkaban AQ R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET</intervention_name>
    <description>fludeoxyglucose F 18 Imaging exam</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <arm_group_label>ABVD + INRT</arm_group_label>
    <other_name>PET/CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>INRT</intervention_name>
    <description>selective external radiation therapy</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <arm_group_label>ABVD + INRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>IV</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <arm_group_label>ABVD + INRT</arm_group_label>
    <other_name>DTIC</other_name>
    <other_name>DTIC-Dome®</other_name>
    <other_name>DIC</other_name>
    <other_name>imidazole carboxamide</other_name>
    <other_name>dimethyl triazeno imidazole carboxamide</other_name>
    <other_name>NSC # 45388</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>IV</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>VePesidÒ</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>EPEG</other_name>
    <other_name>epipodophyllotoxin</other_name>
    <other_name>NSC #141540</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>May be given orally, IV push, or by IV infusion</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <other_name>CytoxanÒ</other_name>
    <other_name>NeosarÒ</other_name>
    <other_name>CTX</other_name>
    <other_name>CPM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>IV</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <other_name>Oncovin R</other_name>
    <other_name>Vincasar PFS R</other_name>
    <other_name>vincristine sulfate</other_name>
    <other_name>VCR</other_name>
    <other_name>leucocristine</other_name>
    <other_name>LCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine</intervention_name>
    <description>PO</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <other_name>MatulaneR</other_name>
    <other_name>Ibenzmethyzin</other_name>
    <other_name>Natulanar</other_name>
    <other_name>N-Methylhydrazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>PO</description>
    <arm_group_label>ABVD + BEACOPP + INRT</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Orasone</other_name>
    <other_name>Medicorten</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Liquid-Pred</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven classical Hodgkin lymphoma subclassified according to the World&#xD;
             Health Organization (WHO) Classification of Tumors, 4th edition (2008)&#xD;
&#xD;
          -  Patients must have clinical stage IA, IB, IIA, or IIB disease&#xD;
&#xD;
               -  Patients with &quot;E&quot; extensions will be eligible if all other criteria have been met&#xD;
&#xD;
          -  Patients must have a mediastinal mass &gt; 0.33-cm maximum intrathoracic diameter on&#xD;
             standing postero-anterior chest x-ray or measuring &gt; 10 cm in its largest diameter on&#xD;
             axial CT images&#xD;
&#xD;
          -  Bone marrow biopsy is required&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Direct bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          -  AST/ALT ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  Women of childbearing potential and sexually active males must be strongly advised to&#xD;
             use an accepted and effective method of contraception&#xD;
&#xD;
          -  LVEF by ECHO or MUGA normal unless thought to be disease related&#xD;
&#xD;
          -  DLCO ≥ 60% with no symptomatic pulmonary disease unless thought to be disease related&#xD;
&#xD;
          -  Patients with a history of intravenous drug abuse, or any behavior associated with an&#xD;
             increased risk of HIV infection, should be tested for exposure to the HIV virus, and&#xD;
             an HIV test is required for entry on this protocol&#xD;
&#xD;
          -  HIV-positive patients are eligible if they have CD4 counts ≥ 400/mm³ and are on&#xD;
             concurrent antiretrovirals&#xD;
&#xD;
               -  Patient HIV status must be known prior to registration&#xD;
&#xD;
               -  HIV-positive patients must not have multi-drug resistant HIV infections; CD4&#xD;
                  counts &lt; 400/mm³; or other concurrent AIDS-defining conditions&#xD;
&#xD;
          -  Concurrent antiretroviral therapy for HIV-positive patients (CD4 counts ≥ 400/mm³)&#xD;
             allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nodular lymphocyte-predominant Hodgkin lymphoma&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  &quot;Currently active&quot; second malignancy other than non-melanoma skin cancers&#xD;
&#xD;
               -  Patients are not considered to have a &quot;currently active&quot; malignancy if they have&#xD;
                  completed therapy and are considered by their physician to be at less than 30%&#xD;
                  risk of relapse&#xD;
&#xD;
          -  Prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjana Advani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <results_first_submitted>October 30, 2020</results_first_submitted>
  <results_first_submitted_qc>December 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2020</results_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Imidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was activated on April 2, 2012 and closed on January 24, 2014 with a final accrual of 6 patients.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ABVD + INRT</title>
          <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.&#xD;
ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.</description>
        </group>
        <group group_id="P2">
          <title>ABVD + BEACOPP + INRT</title>
          <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.&#xD;
BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.</description>
        </group>
        <group group_id="P3">
          <title>Induction ABVD</title>
          <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Step 1: Induction Tx (ABVD Then PET/CT)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Step 2: ABVD or BEACOPP Then INRT</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only eligible and treated patients are included.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A (ABVD + INRT)</title>
          <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.&#xD;
ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.</description>
        </group>
        <group group_id="B2">
          <title>Arm B (ABVD + BEACOPP + INRT)</title>
          <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.&#xD;
BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="39" upper_limit="51"/>
                    <measurement group_id="B2" value="35" lower_limit="35" upper_limit="35"/>
                    <measurement group_id="B3" value="40" lower_limit="35" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival Rate</title>
        <description>Progression-free survival is defined as the time from study entry to lymphoma progression or death from any cause. Proportion of patients who are progression-free and alive at 36 months will be reported. Progression is defined as appearance of any new lesions more than 1.5 cm in any axis, at least a 50% increase from nadir in sum of the product of the diameters (SPD) of any previously involved nodes or extranodal masses or the size of other lesions, or at least 50% increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in its short axis.</description>
        <time_frame>Assessed at 36 months</time_frame>
        <population>Only eligible and treated patients are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ABVD + INRT</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.&#xD;
ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.&#xD;
Doxorubicin: IV&#xD;
Bleomycin: IV&#xD;
Vinblastine: IV&#xD;
PET: fludeoxyglucose F 18 Imaging exam&#xD;
INRT: selective external radiation therapy&#xD;
Dacarbazine: IV</description>
          </group>
          <group group_id="O2">
            <title>ABVD + BEACOPP + INRT</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.&#xD;
BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.&#xD;
Doxorubicin: IV&#xD;
Bleomycin: IV&#xD;
Vinblastine: IV&#xD;
PET: fludeoxyglucose F 18 Imaging exam&#xD;
INRT: selective external radiation therapy&#xD;
Dacarbazine: IV&#xD;
Etoposide: IV&#xD;
Cyclophosphamide: May be given orally, IV push, or by IV infusion&#xD;
Vincristine: IV&#xD;
Procarbazine: PO&#xD;
Prednisone: PO</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Rate</title>
          <description>Progression-free survival is defined as the time from study entry to lymphoma progression or death from any cause. Proportion of patients who are progression-free and alive at 36 months will be reported. Progression is defined as appearance of any new lesions more than 1.5 cm in any axis, at least a 50% increase from nadir in sum of the product of the diameters (SPD) of any previously involved nodes or extranodal masses or the size of other lesions, or at least 50% increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in its short axis.</description>
          <population>Only eligible and treated patients are included in this analysis</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The study was terminated early due to slow accrual. At the time of final analysis, none of the patients were followed for 36 months so 36-month progression-free survival rate could not be reported.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The study was terminated early due to slow accrual. At the time of final analysis, none of the patients were followed for 36 months so 36-month progression-free survival rate could not be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Are PET Negative After Induction Treatment</title>
        <time_frame>Assessed at end of Cycle 2</time_frame>
        <population>Only eligible and treated patients are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Step 1: Induction Tx</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Are PET Negative After Induction Treatment</title>
          <population>Only eligible and treated patients are included in this analysis</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.34" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival at 36 Months Among Patients Who Are PET Positive After Induction Treatment</title>
        <description>Progression-free survival is defined as the time from study entry to lymphoma progression or death from any cause. Proportion of patients who are progression-free and alive at 36 months will be reported. Progression is defined as appearance of any new lesions more than 1.5 cm in any axis, at least a 50% increase from nadir in sum of the product of the diameters (SPD) of any previously involved nodes or extranodal masses or the size of other lesions, or at least 50% increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in its short axis.</description>
        <time_frame>Assessed at 36 months</time_frame>
        <population>Only patients who are PET positive are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ABVD + BEACOPP + INRT</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.&#xD;
BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.&#xD;
Doxorubicin: IV&#xD;
Bleomycin: IV&#xD;
Vinblastine: IV&#xD;
PET: fludeoxyglucose F 18 Imaging exam&#xD;
INRT: selective external radiation therapy&#xD;
Dacarbazine: IV&#xD;
Etoposide: IV&#xD;
Cyclophosphamide: May be given orally, IV push, or by IV infusion&#xD;
Vincristine: IV&#xD;
Procarbazine: PO&#xD;
Prednisone: PO</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 36 Months Among Patients Who Are PET Positive After Induction Treatment</title>
          <description>Progression-free survival is defined as the time from study entry to lymphoma progression or death from any cause. Proportion of patients who are progression-free and alive at 36 months will be reported. Progression is defined as appearance of any new lesions more than 1.5 cm in any axis, at least a 50% increase from nadir in sum of the product of the diameters (SPD) of any previously involved nodes or extranodal masses or the size of other lesions, or at least 50% increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in its short axis.</description>
          <population>Only patients who are PET positive are included in this analysis</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The study was terminated early due to slow accrual. At the time of final analysis, none of the patients were followed for 36 months so 36-month progression-free survival rate could not be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response (CR) Rate After Induction Treatment</title>
        <description>Complete response (CR) is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy.</description>
        <time_frame>Assessed at end of Cycle 2</time_frame>
        <population>Only eligible and treated patients are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Step 1: Induction Tx</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR) Rate After Induction Treatment</title>
          <description>Complete response (CR) is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy.</description>
          <population>Only eligible and treated patients are included in this analysis</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.55" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as the time from study entry to death or date last known alive.</description>
        <time_frame>Assessed at 36 months</time_frame>
        <population>Only eligible and treated patients are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ABVD + INRT</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.&#xD;
ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.&#xD;
Doxorubicin: IV&#xD;
Bleomycin: IV&#xD;
Vinblastine: IV&#xD;
PET: fludeoxyglucose F 18 Imaging exam&#xD;
INRT: selective external radiation therapy&#xD;
Dacarbazine: IV</description>
          </group>
          <group group_id="O2">
            <title>ABVD + BEACOPP + INRT</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.&#xD;
BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.&#xD;
Doxorubicin: IV&#xD;
Bleomycin: IV&#xD;
Vinblastine: IV&#xD;
PET: fludeoxyglucose F 18 Imaging exam&#xD;
INRT: selective external radiation therapy&#xD;
Dacarbazine: IV&#xD;
Etoposide: IV&#xD;
Cyclophosphamide: May be given orally, IV push, or by IV infusion&#xD;
Vincristine: IV&#xD;
Procarbazine: PO&#xD;
Prednisone: PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as the time from study entry to death or date last known alive.</description>
          <population>Only eligible and treated patients are included in this analysis</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median OS was not reached. All patients were alive as of this analysis. The upper and lower limits of the 95% confidence interval were not calculable because an insufficient number of participants reached the event at the final time point for assessment.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median OS was not reached. The patient was alive as of this analysis. The upper and lower limits of the 95% confidence interval were not calculable because an insufficient number of participants reached the event at the final time point for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sites of Relapse Following Combined Modality Treatment</title>
        <time_frame>Assessed at 3, 12, 18, 24 and 36 months after INRT</time_frame>
        <population>The study was terminated early due to slow accrual. Relapse data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>ABVD + INRT</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.&#xD;
ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.&#xD;
Doxorubicin: IV&#xD;
Bleomycin: IV&#xD;
Vinblastine: IV&#xD;
PET: fludeoxyglucose F 18 Imaging exam&#xD;
INRT: selective external radiation therapy&#xD;
Dacarbazine: IV</description>
          </group>
          <group group_id="O2">
            <title>ABVD + BEACOPP + INRT</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.&#xD;
BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.&#xD;
Doxorubicin: IV&#xD;
Bleomycin: IV&#xD;
Vinblastine: IV&#xD;
PET: fludeoxyglucose F 18 Imaging exam&#xD;
INRT: selective external radiation therapy&#xD;
Dacarbazine: IV&#xD;
Etoposide: IV&#xD;
Cyclophosphamide: May be given orally, IV push, or by IV infusion&#xD;
Vincristine: IV&#xD;
Procarbazine: PO&#xD;
Prednisone: PO</description>
          </group>
        </group_list>
        <measure>
          <title>Sites of Relapse Following Combined Modality Treatment</title>
          <population>The study was terminated early due to slow accrual. Relapse data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum and Plasma Banking</title>
        <description>To bank serum and plasma at baseline and follow-up time point to assess the prognostic value of various markers, such as but not limited to, SCD30, IL10, CCL17, CCL22, and MDC.</description>
        <time_frame>Baseline and post cycle 2</time_frame>
        <population>The study was terminated early due to slow accrual. Biomarker data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Step 1: Induction Tx</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Plasma Banking</title>
          <description>To bank serum and plasma at baseline and follow-up time point to assess the prognostic value of various markers, such as but not limited to, SCD30, IL10, CCL17, CCL22, and MDC.</description>
          <population>The study was terminated early due to slow accrual. Biomarker data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Assessment Using Tissue Microarrays (TMAs)</title>
        <description>To create TMAs from patient tumor blocks for future biomarker assessment including but not limited to bcl-2, FOXP3, and macrophage content.</description>
        <time_frame>Baseline and relapse/progression</time_frame>
        <population>The study was terminated early due to slow accrual. Biomarker data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Step 1: Induction Tx</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Assessment Using Tissue Microarrays (TMAs)</title>
          <description>To create TMAs from patient tumor blocks for future biomarker assessment including but not limited to bcl-2, FOXP3, and macrophage content.</description>
          <population>The study was terminated early due to slow accrual. Biomarker data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Association Between Thymus and Activation-related Chemokine (TARC) Levels and PET-CT Findings as Well as 3-year PFS</title>
        <description>To measure serum TARC levels pre-treatment and after two cycles of ABVD and evaluate the associations between TARC levels and PET-CT findings as well as 3-year PFS.</description>
        <time_frame>Baseline and cycle 2 for TARC assessments; 3 years for PFS</time_frame>
        <population>The study was terminated early due to slow accrual. TARC data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Step 1: Induction Tx</title>
            <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.</description>
          </group>
        </group_list>
        <measure>
          <title>The Association Between Thymus and Activation-related Chemokine (TARC) Levels and PET-CT Findings as Well as 3-year PFS</title>
          <description>To measure serum TARC levels pre-treatment and after two cycles of ABVD and evaluate the associations between TARC levels and PET-CT findings as well as 3-year PFS.</description>
          <population>The study was terminated early due to slow accrual. TARC data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every 4 weeks while on treatment and for 30 days after the end of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Step 1: Induction Treatment</title>
          <description>Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.&#xD;
PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). Patients will be assigned to Step 2 treatments (either ABVD + INRT or BEACOPP + INRT) depending on the scan results (negative or positive).</description>
        </group>
        <group group_id="E2">
          <title>Step 2: ABVD + INRT</title>
          <description>ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.</description>
        </group>
        <group group_id="E3">
          <title>Step 2: BEACOPP + INRT</title>
          <description>BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Superficial thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG-ACRIN Biostatistics Center</organization>
      <phone>617-632-3012</phone>
      <email>eatrials@jimmy.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

